Surgery after preoperative chemotherapy for patients with unresectable advanced gastric cancer

Oncology (Switzerland)

Volumn 85, Issue 4, 2013, Pages 241-247

  Yamamoto, Manabu ^a,b   Sakaguchi, Yoshihisa ^b   Matsuyama, Ayumi ^a   Yoshinaga, Keiji ^a   Tsutsui, Shinichi ^a   Ishida, Teruyoshi ^a  

^a ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Gastric cancer; Neoadjuvant; Preoperative chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ABDOMINAL ABSCESS; ADULT; ADVANCED CANCER; ANASTOMOTIC INSUFFICIENCY; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; FEMALE; HAND FOOT SYNDROME; HUMAN; INTESTINE OBSTRUCTION; LEUKOPENIA; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHEDEMA; LYMPHORRHEA; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS FISTULA; PERITONEUM METASTASIS; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK FACTOR; SENSORY NEUROPATHY; STOMACH CANCER; STOMATITIS; SURGICAL INFECTION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR INVASION;

EID: 84885068233     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000354420     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murry T, Thun MJ: Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
2. Kamanger F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.
3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
4. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168.
5. MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C: 5-fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93: 533-536.
6. Findlay M, Cuningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R, Hill A: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5: 609-616.
7. Ohtsu A, Shimoda Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S: Randomized phase III trial of fluorouracil alone vs fluorouracil plus cisplatin vs uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Study (JCOG9205). J Clin Oncol 2003; 21: 54-59.
8. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin vs S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS): a phase III trial. Lancet Oncol 2008; 9: 215-221.
9. Boku N, Yamamoto S, Fukuda H, Shirao K, Sawaki A, Koizumi W, Saitoi H, Yamaguchi K, Takeuchi H, Nasu J, Ohtsu A, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil vs combination of irinotecan plus cisplatin vs S-1 in metastatic gastric cancer. A randomized phase 3 study. Lancet Oncol 2009; 10: 1063-1069.
10. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, Benson AB 3rd: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996; 13: 87-93.
11. Thuss-Patience PC, Kretzchmar A, Reichardt P: Docetaxel in the treatment of gastric cancer. Future Oncol 2009; 10: 603-620.
12. Fushida S, Fujimura T, Oyama K, Yagi Y, Kinoshita J, Ohta T: Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer with paraaortic lymph node metastases. Anticancer Drugs 2009; 20: 752-756.
13. Zang DY, Yang DH, Kim MJ, Jang KM, Hwang SW, Yoo KS, Han T, Kim HY, Kim HJ, Kwon JH, Song HH, Park S, Jung JY, Kim HS, Kim JH: Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. Cancer Chemother Pharmacol 2009; 64: 877-883.
14. Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M, Toge T: Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 2004; 24: 1843-1851.
15. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Toda S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced gastric cancer. Clin Cancer Res 2006; 12: 3402-3407.
16. Kim YH, Koizumi W, Lee KH, Kishimoto T, Chung HC, Hara T, Cho Y, Nakajima T, Kim H, Fujii M: Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): the START trial (board No. A8). Gastrointestinal Cancers Symposium, San Francisco, 2011.
17. Fushida S, Fujimura T, Oyama K, Kinoshita J, Fujita H, Ninomiya I, Ohta T: Neoadjuvanty chemotherapy combining docetaxel, cisplatin, and S-1 in gastric cancer with para-aortic lymph node metastases: report of five cases. Hepatogastroenterology 2010; 57: 1650-1654.
18. Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, Oshita H, Ito S, Kawashima Y, Fukushima N: Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 2009; 96: 1015-1022.
19. Shuhmacher C, Gretshel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelsher A, Schneider PM, Bechstain W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlang PM: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28: 5210-5218.
20. Li W, Qin J, Sun YH, Liu TS: Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol 2010; 16: 5621-5628.
21. Eisenhauer EA, Terasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shanker L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
22. Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101-112.
23. Trotti A, Colevas AD, Setser A, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAC v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
24. Cox DR: Regression models and life tables (with discussion). JR Stat Soc B 1972; 35: 187-220.
25. Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S, Shintani N, Tanaka S, Kida M, Sato Y, Ohta H, Miyanioshi K, Sato T, Takimoto R, Kobune M, Yamaguchi K, Hirata K, Niitsu Y, Kato J: Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 2010; 66: 721-728.
26. Park SR, Kim HK, Kim CG, Choi IJ, Lee JS, Lee JH, Ryu KW, Kim YW, Bae JM, Kim NK: Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. Br J Cancer 2008; 98: 1305-1311.
27. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
28. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Fukukaw H, Yamaguchi T, Nashimoto A, Nakajima T, Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387-4393.
29. Kodera Y, Ishikawa A, Yoshikawa T, Kinoshita T, Ito S, Yokoyama H, Mochizuki Y, Ito H, Tsuburaya A, Sakamoto J, Nakao A: A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma. Gastric Cancer 2010; 13: 197-203.
30. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010; 376: 687-697.
31. Yamashita-Kashima Y, Fujimoto-Ouchi K, Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H, Mori K: Biomarkers for antitumor activity of bevacizumab in gastric cancer models. BMC Cancer 2012; 12: 37.
32. Emi Y, Orita H, Yamamoto M, Sadanaga T, Kusumoto T, Takahashi I, Kakeji Y, Maehara Y: Feasibility of adjuvant S-1 plus docetaxel against stage II-III gastric cancer following R0 resection in gastrectomy. ECCO15, 34th European Society for Medical Oncology multidisciplinary congress, Berlin, 2009.